Autologous Live Cell Technology™
We fully utilize the potential of one’s own cells to offer new solutions in regenerative medicine and orthopedic procedures using Autologous Live Cellular biologics.

What is Autologous Live Cell Technology™?

The ALC Technology portfolio utilizes 2 point of care autologous preparation systems that provide new advanced solutions for the creation of safer, more cost-effective biological solutions over existing industry standards.

FEATURED SYSTEMS

KEY FEATURES
of the FIBRINET SYSTEM

  • The only system that provides intact, concentrated platelets in a platelet-rich fibrin membrane graft without thrombin
  • Sustained availability of platelets and associated growth factors out to seven days; ability to proliferate cells in vitro
  • Easy-to-use, closed system with the highest platelet capture efficiency and reproducibility of all commercially available systems tested
autologous-img-02
  • Ability to mix with bone grafting materials for improved handling characteristics
  • Two separate clinical studies demonstrating 100% radiographic fusion at 12 months

KEY FEATURES
of the Maxx™-Cell SYSTEM

The Maxx™-Cell system maximizes the yield of stem and progenitor cells by giving the clinician the ability to efficiently harvest bone marrow from multiple levels within the medullary space, while restricting dilution of peripheral blood.

autologous-img-01
  • BENEFITS
    Reduce the cost of utilizing high priced biologics. Maxx™-Cell delivers better regenerative solutions at reduced cost compared to industry leading solutions. Create the highest live cellular product, point of care in any clinical setting.
  • MINIMIZE O/R TIME
    Centrifugation systems typically require 20 minutes or more of spin time during the surgical procedure, not to mention the additional support time needed for preparation and cleanup of equipment. No centrifuge needed.
  • MINIMIZE STERILITY CHALLENGES
    Centrifugation systems require passing the BMA off the sterile field for processing and back on for implantation. Maxx™-Cell eliminates the additional steps where infection concerns must be managed.
  • MINIMIZE SAMPLE WASTE
    Centrifugation systems typically discard 80% of the aspirate due to the high levels of peripheral blood. Worse, significant numbers of the desired cells (approx. 40%) are discarded because as these cells increase in density prior to division, they are processed into the undesired red cell centrifuge component and thus discarded, substantially limiting regenerative potential of the resulting sample.